The Cooper Companies, Inc. COO
- Market cap
- $10.5B
- P/E
- 18.9×
Follow COO
The Cooper Companies, Inc. (COO) EV/EBITDA
As of 25 September 2026, The Cooper Companies, Inc. (COO) trades at a EV/EBITDA of 14.1×. Over the past ten years it has ranged from 13.1× (April 2026) to 35.0× (April 2021); the current reading is higher than 1% of that period. That is below the Medical Instruments & Supplies industry median of 16.1× and above the Healthcare sector median of 10.4×.
EV/EBITDA, daily
Annual
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 15.4× | (28.62%) |
| FY2024 | 21.6× | 8.64% |
| FY2023 | 19.8× | 5.09% |
| FY2022 | 18.9× | (30.51%) |
| FY2021 | 27.2× | (6.56%) |
| FY2020 | 29.1× | 49.34% |
| FY2019 | 19.5× | (9.73%) |
| FY2018 | 21.6× | 3.79% |
| FY2017 | 20.8× | 11.12% |
| FY2016 | 18.7× | (9.41%) |
Quarterly
| Period | EV/EBITDA | Change |
|---|---|---|
| Jul 2026 | 17.6× | 6.56% |
| Apr 2026 | 16.5× | (0.32%) |
| Jan 2026 | 16.6× | 7.77% |
| Oct 2025 | 15.4× | 3.96% |
| 43 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| SOLV Solventum Corporation compare | 7.9× |
| ATR AptarGroup, Inc. compare | 11.5× |
| ALGN Align Technology, Inc. compare | 11.7× |
| BAX Baxter International Inc. compare | 13.3× |
| COO The Cooper Companies, Inc. | 14.1× |
| BLCO Bausch + Lomb Corporation compare | 14.4× |
| STVN Stevanato Group S.p.A. compare | 18.1× |
| RGEN Repligen Corporation compare | 65.3× |
| AVTR Avantor, Inc. compare | 110× |
| Medical Instruments & Supplies industry median | 16.1× |
| Healthcare sector median | 10.4× |
| Market median | 11.0× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on COO
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement